Causes of death among commercially insured multiple sclerosis patients in the United States.

by Douglas S Goodin, Michael Corwin, David Kaufman, Howard Golub, Shoshana Reshef, Mark J Rametta, Volker Knappertz, Gary Cutter, Dirk Pleimes
Published 2014-01-01

Establishing long-term efficacy in chronic disease: use of recursive partitioning and propensity score adjustment to estimate outcome in MS.

by Douglas S Goodin, Jason Jones, David Li, Anthony Traboulsee, Anthony T Reder, Karola Beckmann, Andreas Konieczny, Volker Knappertz, 16-Year Long-Term Follow-up Study Investigators
Published 2011-01-01

A pharmacogenetic signature of high response to Copaxone in late-phase clinical-trial cohorts of multiple sclerosis

by Colin J. Ross, Fadi Towfic, Jyoti Shankar, Daphna Laifenfeld, Mathis Thoma, Matthew Davis, Brian Weiner, Rebecca Kusko, Ben Zeskind, Volker Knappertz, Iris Grossman, Michael R. Hayden
Published 2017-05-01